South San Francisco, California, September 26, 2023 – Synlico Inc., an AI-based drug design company focusing on developing potent T-cell therapies against solid tumors, is thrilled to announce its participation in the upcoming 2023 BIO Investor Forum in San Francisco.
In the event, Synlico Inc. will present the development of its computational technology platform, which harnesses state-of-the-art advancements in single-cell bioinformatics, machine learning, and causal discovery. The platform enables a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their shared TME signatures. The platform can design potent T cell therapies by identifying the causal relationship and causal effects between intracellular elements of T cells and their behaviors in patients’ TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments.
Synlico Inc. is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps pharmaceutical and medical technology entrepreneurs bring healthcare solutions to patients and consumers.
“We are excited to share our science and vision at the Bio Investor Forum. Understanding the heterogeneity of the tumor microenvironment is critical to the efficacy of engineered T-cell therapy. Our platform is designed to identify shared patterns among patients, and understand how these TME patterns exert different impacts on T cells.” Jingwei Lu, CEO of Synlico Inc., said. “We also build a causal mapping between interventions of gene regulation of T cells and their behaviors in patients’ TME, which will enable us to find out the optimal design of potent T cell therapies.”
Synlico’s presentation schedule:
- Date: October 17, 2023
- Time: 4:00 pm
- Venue: Room Franciscan C
Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
About Synlico Inc.
Synlico Inc. envisions rewriting medicine by bringing causality to cellular biology. As an AI-powered drug discovery biotech company, Synlico’s primary mission is to develop cutting-edge engineered T cell therapies to combat solid tumors. Harnessing advancements in single-cell bioinformatics, machine learning, and causal discovery, the Synlico team is developing a computational platform that provides a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their unique TME signatures. The Synlico platform will be able to design potent T cell therapies by discovering the causal relationship between intracellular elements of T cells and their behaviors in patients’ TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments. Visit www.synlico.com to find out more.
Synlico Inc. contacts: